Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 November 2019Website:
http://www.89bio.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:24:38 GMTDividend
Analysts recommendations
Institutional Ownership
ETNB Latest News
SAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be featured in four poster presentations at the upcoming 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2024 being held November 15 to 19, 2024 in San Diego, California.
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 8th Annual MASH Investor Conference on Monday, October 7, 2024 at 11:30 AM ET.
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company.
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024.
89bio is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic conditions. Their drug candidate, pegozafermin, has shown positive results in reducing liver fat and insulin resistance and is in phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin has the potential to tap into a large market and has been granted FDA Breakthrough Therapy designation for treating MASH with fibrosis.
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-
The upgrade of 89BIO (ETNB) to a Zacks Rank #2 (Buy) indicates increasing confidence in the company's potential earnings, which could result in a boost in the stock price in the short run.
The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
89bio, Inc.'s successful end-of-phase 2 meeting with the FDA gained alignment for Potential Accelerated Approval of pegozafermin; such studies to be advanced are ENLIGHTEN-Cirrhosis and ENLIGHTEN-Fibrosis. Akero will report 96-week data from the SYMMETRY study of efruxifermin for F4 NASH patients in Q1 of 2024; Success for Akero could mean a boost in value for 89bio. The non-alcoholic steatohepatitis market size is projected to reach $24.26 billion by 2028.
- 1(current)
What type of business is 89bio?
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
What sector is 89bio in?
89bio is in the Healthcare sector
What industry is 89bio in?
89bio is in the Biotechnology industry
What country is 89bio from?
89bio is headquartered in United States
When did 89bio go public?
89bio initial public offering (IPO) was on 11 November 2019
What is 89bio website?
https://www.89bio.com
Is 89bio in the S&P 500?
No, 89bio is not included in the S&P 500 index
Is 89bio in the NASDAQ 100?
No, 89bio is not included in the NASDAQ 100 index
Is 89bio in the Dow Jones?
No, 89bio is not included in the Dow Jones index
When was 89bio the previous earnings report?
No data
When does 89bio earnings report?
The next expected earnings date for 89bio is 08 November 2024